The Enhanced Liver Fibrosis (ELF™) Test

A simple blood test to assess risk of disease progression in advanced fibrosis due to NASH

NAFLD impacts 25% globally.
20% will progress to NASH.1

Because of the increasing disease burden, 
lack of appropriate noninvasive testing
options is a major concern

Nonalcoholic fatty liver disease (NAFLD) can progress into non-alcoholic steatohepatitis (NASH), which can inflame and damage the liver to the point of advanced fibrosis or cirrhosis, dramatically increasing the patient’s risk of liver failure, liver cancer or even death. These risks can be more than twice as high for people living with diabetes, obesity, or high blood pressure.2

Fatty liver disease is increasing in alignment with the increasing rate of obesity, resulting in an exponential burden of disease consequences and a 178% increase in liver related deaths by 2030.3,4 The road to better outcomes is early and frequent prognosis assessment for disease progression in patients with advanced fibrosis (F3 or F4) due to NASH as this helps to identify patients who are the most in need of care.

Assessment of liver fibrosis has traditionally relied on costly and invasive liver biopsy that requires a specialist, may not be representative of the amount of fibrosis, and carries a risk of life-threatening complications.​ Due to these limitations, biopsy is typically used sparingly.

Liber Fibrosis hotspot image
  1. A true silent killer, liver disease often does not show signs or symptoms.

  2. Many patients go undetected and remain in primary care.​

  3. Patient is then referred to a specialist by their PCP​.

  4. Complications of advanced fibrosis start to develop.

  5. More frequent assessment of prognosis is needed for patients with advanced NASH. The evolution of non-invasive liver fibrosis tests has created the opportunity to improve the risk assessment of disease progression helping to ensure patients get the care they need while reducing healthcare costs.

  6. Patient finds out there is severe or irreversible damage and/or is presenting with end stage liver disease​.

Click to watch video

In this video, Dr. Zobair M. Younossi, Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus in Falls Church, Virginia, discusses the epidemiology of NASH, addressing why there is a global need for more awareness and why the current approach to clinical care needs to change.​

The Enhanced Liver Fibrosis (ELF) Blood Test Literature Compendium

As new therapies become available, noninvasive testing is an important tool to help identify patients at risk of progressing to cirrhosis and liver-related clinical events. Learn more about the need for noninvasive tests and how the ELF Test can help.